Sanofi and BioNTech have discontinued the development of an mRNA therapy designed for direct tumor injection. The decision was based on results from an interim analysis, as mentioned in Sanofi’s second quarter earnings report.
The collaboration between the two companies began in 2015, focusing on cancer immunotherapies. In 2019, they initiated a Phase 1 trial for candidate SAR441000, involving 77 patients with advanced solid tumors.
The candidate was tested both as a monotherapy and in combination with Sanofi and Regeneron’s PD-1 checkpoint inhibitor, Libtayo.
Peter Adamson, Sanofi’s head of oncology development and pediatric innovation, had previously expressed optimism about the partnership and anticipated data sharing at a scientific meeting in the first half of the year.
Despite the setback, Sanofi continues its vaccine development efforts, replacing SP0274, an mRNA vaccine for RSV in older adults, with SP0256. The latter, as per a June 29 media release, is one of three assets set to form the basis of a combination vaccine tailored for older adults.
Sanofi also replaced SP0274 , an mRNA vaccine in Phase I for RSV in older adults, with SP0256 . In a June 29 media release, the company said SP0256 is one of three assets that would “lay the foundation” of a combination vaccine for older adults.
Sanofi, BioNTech
